FDGal PET/CT to Detect Hepatocellular Carcinoma

Inclusion Criteria:

* Male or female, age ≥ 19 years of age.
* Patient who accepts to enter the study by signing written informed consent.
* Patient with performance status ≤ 2 Eastern Cooperative Oncology Group (ECOG).
* Patient with cirrhosis or chronic liver disease suspected to have at least 1 hepatic nodule larger than 1 cm in diameter detected by conventional image (US, CT, MRI).

  * Hepatic nodule is defined as any one of the following conditions: suspicious hepatocellular carcinoma, benign tumor such as hemangioma, adenoma or focal nodular hyperplasia, possible metastatic lesions from other primary malignancy.

Exclusion Criteria:

* Patient has serious allergic history or known allergy to 18F-FDGal or 18F-FDG.
* Patient has received therapy for aforementioned diagnosis before the PET scans
* Patient with known (proven) metastases from a prior malignancy
* Patient has been diagnosed with multiple malignancies.
* Female patient who is pregnant, lactating or planning to become pregnant during the study.
* Patient has participated in other investigational trials within 28 days prior to study enrollment.
* Inability to lie supine for the duration of the imaging studies.
* Subject with active systemic infections, or medical conditions that may significantly affect adequate uptake and elimination of radiotracer.
* Subject with conditions judged by the investigator as unsuitable for the study.